\nSimulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2021.\n<\/p>\n
\nFinancial highlights compared with the corresponding period last fiscal year:\n<\/p>\n
- \n
- \nRevenue increased 14% to $10.7 million\n<\/li>\n
- \nGross profit increased 22% to $8.3 million\n<\/li>\n
- \nGross margin was 77%, up from 72%\n<\/li>\n
- \nNet income increased 21% to $2.5 million\n<\/li>\n
- \nDiluted earnings per share increased 9% to $0.12\n<\/li>\n<\/ul>\n
\nShawn O\u2019Connor, chief executive officer of Simulations Plus, said: \u201cOur first quarter financial results were in line with our expectations highlighted by strong, double-digit revenue growth and increased profitability, despite a challenging comparison to the first quarter of fiscal 2020 that benefited from unusually strong results in our DILIsym division. The strategic investments in our sales and marketing infrastructure, and a growing reliance on modeling and simulation in the drug development ecosystem continue to facilitate strong revenue growth, as Simulations Plus bolsters its already strong position in the marketplace. The acquisition of Lixoft has meaningfully expanded our addressable market. In addition, this acquisition has had the desired impact of increasing the mix of software revenue, helping expand our overall profitability.\u201d\n<\/p>\n
\n\u201cWe recently signed a large COVID-19-related consulting services project with a large pharmaceutical client, validating the resources we devoted to our COVID-19 initiative and demonstrating the increasing value we play in support of our clients,\u201d added Mr. O\u2019Connor. \u201cWe also signed a new three-year project with a large private foundation as well as three new projects with a large non-profit biotechnology institute. Looking ahead, demand for our consulting services remains strong and next generation releases of several of our software products that are scheduled for fiscal 2021 reinforce our confidence in delivering another year of organic growth of 15% to 20% in fiscal 2021.\u201d\n<\/p>\n
Quarterly Dividend Declared<\/b><\/p>\n
\nThe Company\u2019s Board of Directors has declared a cash dividend of $0.06 per share of the Company\u2019s common stock payable on February 1, 2021, to shareholders of record as of January 25, 2021. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.\n<\/p>\n
Investor Conference Call<\/b><\/p>\n
\nThe Company has announced an investor conference call that will be webcast live at 1:15 p.m. PST\/4:15 p.m. EST on Monday, January 11, 2021. The live webcast\/teleconference will be accessible by here<\/a> or by calling 1-201-389-0879. Please join 5 to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations<\/a>. A replay of the webcast will be available on the website approximately one hour following the call.\n<\/p>\n
About Simulations Plus, Inc.<\/b><\/p>\n
\nSimulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen<\/a>, DILIsym Services<\/a>, and Lixoft<\/a>, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology\/toxicology, and population PK\/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com<\/a>.\n<\/p>\n
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995<\/b> \u2013 With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of our new software products as well as improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.\n<\/p>\n
\nFollow us on Twitter<\/a> | LinkedIn<\/a> | YouTube<\/a><\/p>\n
\n–Tables follow —\n<\/p>\n
\n
\n SIMULATIONS PLUS, INC. <\/b><\/td>\n<\/tr>\n \n CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)<\/b><\/td>\n<\/tr>\n \n For the three months ended November 30,<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n (in thousands, except per common share amounts)<\/td>\n \n \n 2020<\/b><\/p>\n<\/td>\n
\n \n 2019<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Revenues<\/b><\/td>\n \n \n \n$\n<\/p>\n<\/td>\n
\n \n10,701\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n$\n<\/p>\n<\/td>\n
\n \n9,401\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Cost of revenues<\/b><\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,433\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,643\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Gross margin<\/b><\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n8,268\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n6,758\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating expenses<\/b><\/td>\n \n \n \n <\/tr>\n \n Selling, general, and administrative<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n4,408\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n3,514\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Research and development<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n809\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n526\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total operating expenses<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n5,217\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n4,040\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Income from operations<\/b><\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n3,051\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,718\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Other income (expense)<\/b><\/td>\n \n \n \n <\/tr>\n \n Interest income<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n61\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n11\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Change in value of contingent consideration<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n(121\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n\u2014\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Income on currency exchange<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n5\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n4\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total other income (expense)<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n(55\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n15\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Income before provision for income taxes <\/b><\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,996\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,733\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Provision for income taxes<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n(517\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n(675\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n Net income<\/b><\/td>\n \n \n $<\/b><\/p>\n<\/td>\n
\n 2,479<\/b><\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n $<\/b><\/p>\n<\/td>\n
\n 2,058<\/b><\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Earnings per share<\/b><\/td>\n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n \n$\n<\/p>\n<\/td>\n
\n \n0.12\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n$\n<\/p>\n<\/td>\n
\n \n0.12\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Diluted<\/td>\n \n \n \n$\n<\/p>\n<\/td>\n
\n \n0.12\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n$\n<\/p>\n<\/td>\n
\n \n0.11\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Weighted-average common shares outstanding <\/b><\/td>\n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n19,930\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n17,609\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Diluted<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n20,799\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n18,307\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n SIMULATIONS PLUS, INC. <\/b><\/td>\n<\/tr>\n \n CONDENSED CONSOLIDATED BALANCE SHEETS<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n (Unaudited)<\/b><\/td>\n \n (Audited)<\/b><\/td>\n<\/tr>\n \n (in thousands, except share and per share amounts)<\/td>\n \n November 30,<\/b><\/td>\n \n August 31,<\/b><\/td>\n<\/tr>\n \n ASSETS<\/b><\/td>\n \n \n \n <\/tr>\n \n \n \n \n 2020<\/span><\/b><\/p>\n<\/td>\n
\n \n 2020<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n
\n Current assets<\/b><\/td>\n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n \n \n$\n<\/p>\n<\/td>\n
\n \n27,651\n<\/p>\n<\/td>\n
\n \n \n$\n<\/p>\n<\/td>\n
\n \n49,207\n<\/p>\n<\/td>\n<\/tr>\n
\n Accounts receivable, net of allowance for doubtful accounts of $50 and $50<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n7,331\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n7,422\n<\/p>\n<\/td>\n<\/tr>\n
\n Revenues in excess of billings<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,837\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n3,093\n<\/p>\n<\/td>\n<\/tr>\n
\n Prepaid income taxes<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n560\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n970\n<\/p>\n<\/td>\n<\/tr>\n
\n Prepaid expenses and other current assets<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n1,738\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n1,596\n<\/p>\n<\/td>\n<\/tr>\n
\n Short-term investments<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n91,115\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n66,804\n<\/p>\n<\/td>\n<\/tr>\n
\n Total current assets<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n131,232\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n129,092\n<\/p>\n<\/td>\n<\/tr>\n
\n Long-term assets<\/b><\/td>\n \n \n \n <\/tr>\n \n Capitalized computer software development costs, net of accumulated amortization of $13,906 and $13,582<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n6,490\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n6,087\n<\/p>\n<\/td>\n<\/tr>\n
\n Property and equipment, net<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n596\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n438\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease right of use assets<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n768\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n927\n<\/p>\n<\/td>\n<\/tr>\n
\n Intellectual property, net of accumulated amortization of $5,444 and $5,087<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n11,541\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n11,898\n<\/p>\n<\/td>\n<\/tr>\n
\n Other intangible assets, net of accumulated amortization of $1,779 and $1,642<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n6,871\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n7,008\n<\/p>\n<\/td>\n<\/tr>\n
\n Goodwill<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n12,921\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n12,921\n<\/p>\n<\/td>\n<\/tr>\n
\n Other assets<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n51\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n51\n<\/p>\n<\/td>\n<\/tr>\n
\n Total assets<\/b><\/td>\n \n \n $<\/b><\/p>\n<\/td>\n
\n 170,470<\/b><\/p>\n<\/td>\n
\n \n $<\/b><\/p>\n<\/td>\n
\n 168,422<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n LIABILITIES AND SHAREHOLDERS’ EQUITY<\/b><\/td>\n \n \n \n <\/tr>\n \n Current liabilities<\/b><\/td>\n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n \n \n$\n<\/p>\n<\/td>\n
\n \n332\n<\/p>\n<\/td>\n
\n \n \n$\n<\/p>\n<\/td>\n
\n \n351\n<\/p>\n<\/td>\n<\/tr>\n
\n Accrued payroll and other expenses<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,300\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,251\n<\/p>\n<\/td>\n<\/tr>\n
\n Current portion – contracts payable<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,000\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,000\n<\/p>\n<\/td>\n<\/tr>\n
\n Billings in excess of revenues<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n206\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n141\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease liability, current portion<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n395\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n463\n<\/p>\n<\/td>\n<\/tr>\n
\n Deferred revenue<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n244\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n300\n<\/p>\n<\/td>\n<\/tr>\n
\n Total current liabilities<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n5,477\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n5,506\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Long-term liabilities<\/b><\/td>\n \n \n \n <\/tr>\n \n Deferred income taxes, net<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,401\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n2,354\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease liability<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n376\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n463\n<\/p>\n<\/td>\n<\/tr>\n
\n Payments due under contracts payable<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n4,185\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n4,064\n<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n12,439\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n12,387\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Commitments and contingencies <\/b><\/td>\n \n \n \n <\/tr>\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Shareholders’ equity<\/b><\/td>\n \n \n \n <\/tr>\n \n Preferred stock, $0.001 par value 10,000,000 shares authorized, no shares issued and outstanding<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n–\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n–\n<\/p>\n<\/td>\n<\/tr>\n
\n Common stock, $0.001 par value and additional paid in capital \u2014 50,000,000 shares authorized, 19,958,760 and 19,923,277 shares issued and outstanding<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n129,253\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n128,541\n<\/p>\n<\/td>\n<\/tr>\n
\n Retained earnings<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n28,720\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n27,436\n<\/p>\n<\/td>\n<\/tr>\n
\n Accumulated other comprehensive income<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n58\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n58\n<\/p>\n<\/td>\n<\/tr>\n
\n Total shareholders’ equity<\/td>\n \n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n158,031\n<\/p>\n<\/td>\n
\n \n \n\u00a0\n<\/p>\n<\/td>\n
\n \n156,035\n<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities and shareholders’ equity<\/b><\/td>\n \n \n $<\/b><\/p>\n<\/td>\n
\n 170,470<\/b><\/p>\n<\/td>\n
\n \n $<\/b><\/p>\n<\/td>\n
\n 168,422<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210111005233\/en\/<\/a><\/span><\/p>\n
Simulations Plus Investor Relations
\n<\/span>
Ms. Renee Bouche
\n
661-723-7723
\n
renee@simulations-plus.com<\/a><\/p>\nHayden IR
\n<\/span>
Mr. Cameron Donahue
\n
651-653-1854
\n
slp@haydenir.com<\/a><\/p>\nKEYWORDS:<\/b> California United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Professional Services Health Technology Software Consulting Pharmaceutical Biotechnology<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210111005233\/en\/836572\/3\/BusinessWireLogo.jpg\")
<\/td>\n<\/tr>\n